Galeana-de-la-Rosa JE, Cruz-Cardona A, Martínez-Aguilar J, Cupul-Flores LJ, Rodríguez-Rivero CJ

Language: Spanish
References: 10
Page: 23-26
PDF size: 442.47 Kb.

ABSTRACT

Introduction. Methotrexate (MTX) is an essential drug in the treatment of acute lymphoblastic leukemia (ALLL). Like all other drugs, its use is not without potential adverse effects such as neurotoxicity (NT). In addition to the inherent risk of the drug, concomitant use of certain substances may increase serum MTX concentrations, which increases the risk of developing NT. Reducing vitamin B12 levels is one of the mechanisms involved in NT development. It has been reported in the literature that dextromethorphan (DXM) is a useful drug for reversing this adverse effect.
Clinical case: We report a case of a 10-year-old female with high risk ALL who presents subacute MTX NT data two weeks after receiving high dose MTX consolidation therapy; NT was reversed within 12 hours of initiating DXM.
Conclusion. A quick retrieval of the NT frame by MTX was obtained after the administration of DXM, as reported in literature. Therefore, DXM treatment can be considered as a therapeutic option for subacute NT by MTX. MTX NT is a rare condition in this group of patients, so this publication is expected to contribute to the spread of NT and its treatment, as well as to lead to future research.

REFERENCES

1. Bhojwani D, Sabin ND, Pei D, Yang JJ, Khan RB, Panetta Jc, et al.Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. Journal of Clinical Oncology. 2014; 32 (9): 949-959.

2. Vezmar S, Becker A, Bode U, Jaehde U. Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy. 2003; 49(1-2): p. 92-104.

3. Milman N. Intestinal absorption of folic acid- new physiologic & molecular aspects. Indian J Med Res. 2012; 136(5): p. 725-728.

4. Forster J, Van Delft FW, Baird SF, Mair S, Skinner R, Halsey C. Drug interactions may be important risk factors for methotrexate neurotoxity, particularly in pediatric leukemia patients. Cancer Chemotherapy and Pharmacology. 2016; 78(5): p. 1093-1096.

5. Drachtman RA, Golden CB, James J, Aisner J. Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity. Pediatric Hematology and Oncology. 2002; 19(5):319-27.

6. García-Puig OCM, Fons-Estupiña, MC, Rives-Solà S, Berrueco-Moreno R, Cruz-Martínez O, Campistol J. Neurotoxicidad por metotrexato en pacientes pediátricos. Descripción de los síntomas clínicos y hallazgos neurorradiológicos. Rev Neurol. 2012; 54(12): p. 712-718.

7. Newton HB. Neurological complications of chemotherapy to the central nervous system. Handb Clin Neurol. 2012; 105.

8. Forster VJ, McDonnell A, Theobald R, McKay JA. Effect of methotrexate/ vitamin B12 on DNA methylation as a potential factor in leukemia treatmentrelated neurotoxicity. Epigenomics. 2017; 9(9): p. 1-14.

9. Afshar M, Birnbaum D, Golden C. Review of dextromethorphan administration in 18 patients with subacute methotrexate central nervous system toxicity. Pediatric Neurology. 2014; 50: p. 625-629.

10. Coker A, Pastel DA, Davis MC, Bengtson M, Fadul CE, Lewis LD. Methotrexate encephalopathy: Two cases in adult cancer patients, who recovered with pathophysiologically based therapy. SAGE Open Medical Case Reports. 2017; 5: p. 1-4.